Dezocine

Summary

Dezocine (CHEMBL1685) is an approved small-molecule opioid analgesic (ATC N02AX03); indicated across 1 condition.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N02AX03
• Indications: 1 condition
• Clinical trials: 10
• Chemistry: 245.36 Da · C16H23NO

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1685
Name	Dezocine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	3033053
ChEBI	CHEBI:4474
ATC	N02AX03
Molecular formula	C16H23NO
Molecular weight	245.36
InChIKey	VTMVHDZWSFQSQP-VBNZEHGJSA-N

SMILES: C[C@]12CCCCC[C@H]([C@@H]1N)CC3=C2C=C(C=C3)O

IUPAC name: (1R,9S,15S)-15-amino-1-methyltricyclo[7.5.1.02,7]pentadeca-2(7),3,5-trien-4-ol

ChEBI definition: (7S,8S)-7-Amino-8-methyl-5,6,7,8-tetrahydronaphthalen-2-ol in which the hydrogen at position 8 and one of the hydrogens at position 6 are substituted by each end of a tetramethylene bridge. A synthetic opioid analgesic, it has mixed opiod agonist and antagonist properties. Although it is used for pain management, it can produce opioid withdrawal syndrome in patients already dependent on other opioids, and its clinical application is limited by side effects such as dizziness.

Pharmacological roles (ChEBI): opioid analgesic.

Also known as: Dalgan, Dezocina, Dezocine, Docozine, Dozocine, WY-16,225, WY-16225, dezocine, DEZOCINE, (+)-Dezocine

Patent coverage: 2,610 distinct patent families (11,650 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 11,649 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 1 (assay-derived). Sample: Mu-type opioid receptor.

Bioactivity

ChEMBL activities: 7 potent at pChembl ≥ 5 of 7 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
OPRM1	9.27	Ki	0.54	nM	CHEMBL_ACT_27066959
OPRM1	9.27	Ki	0.54	nM	CHEMBL_ACT_27465305
OPRM1	7.7	EC50	20	nM	CHEMBL_ACT_27066962
OPRM1	7.7	EC50	20	nM	CHEMBL_ACT_27465308
OPRM1	7.42	EC50	38	nM	CHEMBL_ACT_2607521
OPRM1	6.89	IC50	130	nM	CHEMBL_ACT_27066965
OPRM1	6.89	IC50	130	nM	CHEMBL_ACT_27465311

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 10.

Phase distribution

Phase	Trials
PHASE4	6
Not specified	4

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06439368	PHASE4	RECRUITING	Effect of Dezocine Combined With Sufentanil on the Quality of Postoperative Recovery and Analgesic Effect in Patients Undergoing Thoracic Surgery
NCT02673723	PHASE4	COMPLETED	The Application of Docozine Combined With Sufentanil for Awake Tracheal Intubation
NCT03014713	PHASE4	UNKNOWN	Effect of Dexmedetomidine for Postoperative Intravenous Patient Controlled Analgesia
NCT03147066	PHASE4	COMPLETED	Dezocine for Prevention of Catheter-related Bladder Discomfort
NCT05515822	PHASE4	UNKNOWN	Use of Oxycodone in Bariatric Surgery
NCT05861063	PHASE4	UNKNOWN	The Efficacy and Safety of Dezocine Pretreatment for Pain Relief in Acne Scar Treatment of Fractional CO2 Laser
NCT07401641	Not specified	RECRUITING	Effect of Dezocine Versus Nalbuphine Combined With Sufentanil on Postoperative Analgesia, Complications, and Free Flap Survival in Patients Undergoing Oral Cancer Radical Surgery: A Randomized Controlled Clinical Trial.
NCT02768168	Not specified	COMPLETED	The Effects of Dezocine Pretreatment on Dexamethasone Induced Perineal Irritation
NCT04906317	Not specified	UNKNOWN	The Effectiveness of Sedation and Analgesia in Colonoscopy Treatment of Colorectal Polyps
NCT06000137	Not specified	COMPLETED	The Comparison of the Analgesic Effects of Dezocine and Sufentanil in Patient-controlled Analgesia After Laryngectomy

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).